A new scoping review of the research on kratom’s online presence has documented a consistent pattern: across social media, vendor websites, and discussion forums, kratom and kratom-derived products are marketed heavily around their claimed benefits, while information about risks like dependence and withdrawal is inconsistent or missing. The review, currently posted as a preprint undergoing open peer review at JMIR Infodemiology, was conducted by researchers Abhay Dharanikota, Mahati Dharanikota, Sajan Parikh, and Vraj Patel, and offers one of the more systematic looks yet at the specific language and framing used to sell kratom products online, as distinct from the separate question of what the clinical research says about the plant itself.
The researchers followed a recognized methodology for evidence reviews, PRISMA-ScR, searching the Scopus database and a university library discovery system before screening the results down from an initial 2,920 unique records to a final set of 20 empirical studies that met their criteria. To qualify, a study had to focus on kratom, 7-hydroxymitragynine (7-OH), mitragynine, or mitragynine pseudoindoxyl, and had to empirically analyze an actual online information environment, such as Reddit threads, Facebook groups, YouTube content, Erowid experience reports, FDA public comment submissions, vendor product pages, or online marketplaces, rather than relying on general commentary or offline survey data alone.
What that body of research found, according to the review, is that kratom is “frequently framed as self-treatment, harm reduction, natural wellness, functional enhancement, or a safer alternative to regulated substances” across the platforms studied. The specific reasons people online say they use kratom cluster around a handful of recurring themes: pain management, anxiety or low mood, easing opioid withdrawal, and boosting energy or focus. That framing is consistent with how kratom is widely discussed in consumer and advocacy spaces, positioning it as a natural, functional option rather than a pharmaceutical one.
The gap the researchers highlight is not in whether these benefit claims exist online, since the review confirms they are common, but in what tends to be left out alongside them. Looking specifically at vendor and product-marketing content, the studies included in the review found incomplete consumer health information generally, limited balanced risk communication, and inconsistent disclosure of dependence and withdrawal risks. In plain terms, the marketing side of the equation was well represented in the sources reviewed; the risk-communication side, less so.
The review draws a distinction that is worth sitting with rather than skimming past: traditional kratom leaf and powder, the form most associated with decades of use in Southeast Asia and with most of the harm-reduction and self-treatment discussion online, is not the same as newer concentrated products built around 7-OH or mitragynine pseudoindoxyl. Those concentrated products, along with consumer-friendly formats like ready-to-drink beverages, gummies, tablets, and strips, are frequently marketed under the same general “kratom” label as traditional leaf and powder, despite differing in composition. The researchers flag that as a particular concern given how those formats can appeal to younger consumers.
None of this is presented in the review as evidence that kratom itself is unsafe or that the people discussing it online are being deliberately misleading. The authors describe the overall body of digital-environment research on kratom as “small but coherent,” and their conclusion is a fairly narrow one: online discourse tends to present kratom in favorable, functional terms, while the risk communication that accompanies it is inconsistent across sources. That is a statement about information quality and completeness, not a verdict on the substance itself, and the review does not attempt to settle open scientific questions about kratom’s safety profile that lie outside its scope.
It’s also worth being clear about what this kind of review can and can’t tell readers. A scoping review like this one is a map of the existing research landscape rather than a new experiment of its own; the researchers’ job was to find and characterize the 20 qualifying studies, not to independently verify every claim inside them. The screening process was deliberately narrow, excluding narrative reviews, opinion pieces, government agency webpages, and offline clinical or toxicology research that didn’t specifically analyze an online information environment. That narrower focus is what let the authors make a specific claim about marketing versus risk communication online, but it also means the review says little about how kratom is discussed in person, in print media, or through other channels not captured by the 20 studies.
Where the review is more directly useful is in what it recommends for people trying to make informed decisions, including clinicians talking with patients who use kratom. Rather than treating kratom use as a single yes-or-no question, the authors suggest asking what specific product form someone is using, why they are using it, where they learned about it, and whether they understand the risks tied to product variability, dependence, withdrawal, and combining kratom with other substances. That kind of specificity matters precisely because the review found that marketing narratives don’t reliably distinguish between, say, a cup of traditional kratom tea and a concentrated 7-OH extract sold under similar branding.
The authors also point to a gap in the research itself: their review notes that future work in this area should look more closely at short-form video platforms and other performance-oriented marketing formats, which were not well represented in the 20 studies they were able to include. Given how much consumer information now moves through short video content rather than static vendor pages or long-form forum posts, that is a meaningful blind spot in the current evidence base, and one the authors identify as a priority for future research rather than something the current review was able to answer.
For readers trying to separate marketing from evidence, the practical takeaway from this review is less about any single claim and more about a pattern: when a product is discussed primarily in terms of its benefits, and less often in terms of dependence, withdrawal, product variability, or how it differs from newer concentrated alternatives, that is a sign to look for more complete information elsewhere before deciding what to believe. Consumer education, quality labeling, and consistent risk communication are frequently cited as the more evidence-based path forward, as opposed to leaning on marketing copy alone to answer questions that research is still working through.
That distinction between marketing language and evidence is also, in a narrower sense, a labeling and standards question, not just a media-literacy one. If concentrated alkaloid products and traditional leaf or powder are being sold under overlapping branding, as the review suggests, then the clearest way to close the information gap it identifies is not to ask consumers to become more skeptical readers of vendor copy, but to make the product itself say more: clear labeling of form and concentration, consistent disclosure of what is and isn’t known about dependence and withdrawal, and product-specific information rather than a single blanket narrative applied to everything sold under the kratom name. Until that kind of standardization is more consistent across the market, reviews like this one function as a useful, if incomplete, substitute: a record of what the research says is actually being communicated to people deciding whether, and how, to use these products.